Compare SDRL & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDRL | NKTR |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2018 | 1996 |
| Metric | SDRL | NKTR |
|---|---|---|
| Price | $39.91 | $72.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $56.00 | ★ $146.67 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,437,000,000.00 | $307,711,000.00 |
| Revenue This Year | $5.22 | N/A |
| Revenue Next Year | $16.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.75 | ★ 86.00 |
| 52 Week Low | $27.40 | $21.02 |
| 52 Week High | $55.47 | $109.00 |
| Indicator | SDRL | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 58.44 |
| Support Level | $28.94 | $64.30 |
| Resistance Level | $40.16 | $76.67 |
| Average True Range (ATR) | 1.63 | 4.21 |
| MACD | 0.41 | 1.49 |
| Stochastic Oscillator | 75.28 | 71.74 |
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, and others. The company derives maximum revenue from Brazil.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.